PARACETAMOL 125MG + PHENYLEPHRINE HCL 2.5MG + CHLORPHENIRAMINE MALEATE 1.0MG DROPS is a multi-component pharmaceutical liquid formulation comprising Paracetamol, Phenylephrine Hydrochloride, and Chlorpheniramine Maleate in a concentrated oral-drop dosage form. Such a formulation typically requires tight control over active-ingredient concentration, liquid uniformity, excipient compatibility, viscosity, pH, and packaging performance.
The formulation contains Paracetamol 125MG, Phenylephrine HCl 2.5MG, and Chlorpheniramine Maleate 1.0MG in accordance with the stated composition. Due to the liquid form of the ingredients, accurate dissolution or dispersion and maintained concentration throughout the batch are critical formulation-development goals.
Appropriate pharmaceutical excipients might include purified water, sweetening agents, flavoring agents, buffering agents, preservatives, solubilizing agents, viscosity modifiers, and any other formulation aids as dictated by the final composition.
Oral drops typically require accurate dispensing characteristics since the product is presented in small volumes per dose. Consequently, the formulation and dropper system should be optimized in tandem for consistent product presentation and predictable liquid delivery characteristics.
Development of PARACETAMOL 125MG + PHENYLEPHRINE HCL 2.5MG + CHLORPHENIRAMINE MALEATE 1.0MG DROPS depends on an assessment of the physicochemical properties of each API. Solubility, pH behavior, particle (where relevant) characteristics, moisture sensitivity, and compatibility with the planned excipients can be studied during preformulating.
Phenylephrine Hydrochloride and Chlorpheniramine Maleate can be integrated into an aqueous pharmaceutical system based on the eventual formulation design. Paracetamol might need extra attention during development to keep formulation concentrations in check and accommodate solubility limits within the liquid system.
An appropriate co-solvent or solubilizer system can be used if supported by formulation screening. Buffering agents can also be considered for establishing the pH range and stabilizing the formulation.
Excipients should be chosen to prevent negative interactions with active ingredients. Flavors and sweeteners can be added for the desired organoleptic properties, with viscosity-modifying agents considered if the formulation application requires it.
The final liquid should remain uniform and physically stable throughout storage under specified conditions.
Manufacturing begins with the receipt, identification, sampling, testing, and approval of raw materials, followed by weighing to form the master formula. Active ingredients and excipients are added to the manufacturing vessel in accurately weighed quantities.
Purified water or another solvent vehicle is added to the vessel, with soluble excipients dissolved as needed. Paracetamol, Phenylephrine HCl, and Chlorpheniramine Maleate are blended according to their respective protocols. Mixing occurs until the liquid is as homogeneous as possible.
Mixing speeds and durations are designed to ensure thorough distribution without excessive heat generation. Additional excipients such as flavorings, sweeteners, pH buffering substances, preservatives, and viscosity enhancers can be incorporated subsequently.
The bulk can be filtered if necessary and samples analyzed for appearance and uniformity. This ensures that each part of the bulk maintains the right quality before moving to the bottling process. Ongoing process checks could include measurements of viscosity, pH, fill-volume, and homogeneity.
Quality control assessments of PARACETAMOL 125MG + PHENYLEPHRINE HCL 2.5MG + CHLORPHENIRAMINE MALEATE 1.0MG DROPS follow standardized procedures for assuring the chemical, physical, and microbiological integrity of the pharmaceutical product. Identification of individual APIs, assays, related compounds, and microbial health checks are performed against specifications.
Uniformity testing of the liquid is necessary to verify that the entire bulk is consistent, reflecting appropriate distribution of each active pharmaceutical ingredient. This is crucial, especially given the multiple components involved.
Dropper evaluation involves testing for drop size, consistent release, and other factors such as leakage and compatibility with the liquid. Fill-volume testing ensures each bottle has the specified amount of product. The observed physical appearance of the finished product should be uniform, free of unwanted sediment, clouding, or changes.
Stability testing involves analyzing physical, chemical, and microbial stability over time under known storage conditions, providing data to optimize shelf-life and package selection. Selecting a compatible container closure system that does not interact with the formulation and maintains product stability is an integral part of the production process.
Packaging will include the appropriate dosage and product details, with inclusion of regulatory information. Formulation components like flavors and sweeteners, as well as colorants and preservatives if needed, should be compatible with the other formulation ingredients and require validation.
PARACETAMOL 125MG + PHENYLEPHRINE HCL 2.5MG + CHLORPHENIRAMINE MALEATE 1.0MG DROPS can be offered as part of a pharmaceutical product portfolio comprising tablets, capsules, syrups, dry syrups, suspensions, oral drops, creams, ointments, and other forms. Drops offer a distinct dosage and delivery challenge, focusing on liquid uniformity, controlled concentration, and reliable delivery.
A comprehensive approach to development and manufacturing spans raw material selection and approval, mass preparation, quality control, sterile production, filling, packaging, quality assurance, and document management. Each step supports the goal of delivering a high-quality finished pharmaceutical product.
For any multi-active pharmaceutical product in liquid form, analytical precision becomes even more critical since multiple APIs with different specifications are present. This, coupled with the visual and functional packaging characteristics, helps ensure that the entire pharmaceutical product range is reliable and professional.
For companies intending to build or enhance their PCD Pharma Franchise portfolio, this product presents a promising addition. With the correct formulation strategy, rigorous quality controls, and stable manufacturing processes, it can be a core product within a reliably manufactured portfolio.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech